After Teva (TEVA) won a favorable judgment from a court on its Treanda patent, RBC Capital says that the ruling will protect Eagle's (EGRX) BENDEKA royalties. The firm adds that Eagle will now be able to focus more intently on other priorities. Despite the 28% jump in Eagle's stock in the wake of the news, RBC says it remains upbeat on the company's stock, citing several "important product updates" expected to occur this year. RBC keeps a $78 price target and Outperform rating on the shares.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."